Study participants
Tumors
TUMORS, ONCOLOGY, SOLID TUMOR
Eligible patients were males or females ≥18 years of age with a histologically or cytologically confirmed metastatic or locally advanced solid tumor, for which no effective standard therapy exists, or had previously failed treatment. Eligible patients had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Patients were not previously treated with FGF19‐FGFR4 therapy/pan‐FGFR inhibitor. Eligible patients had no impairment of gastrointestinal function/ongoing active diarrhea/irritable bowel syndrome that could alter EVER4010001 absorption. All patients had provided written informed consent.